Sage Therapeutics, Inc. and Biogen, Inc. have again pushed out their filing plans for the antidepressant zuranolone, but their plan provides a clearer – albeit slightly riskier – path to market than before.
The companies said 19 October that they would file with the US Food and Drug Administration for zuranolone in major...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
